Join
Live feed
·
INSIDERFilingvia Quantisnow
Denali Therapeutics Inc. logo

Director Krognes Steve E. sold $607,500 worth of shares (30,000 units at $20.25), decreasing direct ownership by 51% to 29,096 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
DNLI· Denali Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track DNLI (Denali Therapeutics Inc.) and more on Quantisnow.